Parabilis Medicines, Inc. (PBLS) Stock Price & Analysis
Parabilis Medicines, Inc. (PBLS) closed at USD 26.92 on Thursday, October 22, 2026, down 3.34% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 27.85; the Oct 22, 2026 session ranged USD 26.58–28.29 on volume of 911,946 shares. Market capitalization is $3.33B, with a 52-week range of USD 22.66–42.49 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:31 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PBLS.md
Key facts (PBLS)
- Insider open-market purchases, last ~7 months: 5 Form 4 filings, $441M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 41.4 (range 40–45).
- Total return with dividends: 1Y -14.8% vs S&P 500 +14.9%; 5Y -1.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.38, revenue estimate $500K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PBLS)
P/B 3.2x · Earnings yield -5.14% · Net cash $1.11B · EV $2.21B
Insider purchases (SEC Form 4, open-market, last ~7 months) (PBLS)
5 purchases, $441M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-20…2026-07-22 | Ra Capital Management, L.P. | Director | 244,593 | $6.9M | 28.29 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-12…2026-06-15 | Sebulsky Alan | Director | 17,500 | $474K | 27.06 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Levy Guy | 500,000 | $10.0M | 20 | Too little history (no open-market trades in 2023–2025) | |
| 2026-06-11 | Ra Capital Management, L.P. | Director | 21,188,750 | $424M | 20 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Sebulsky Alan | Director | 12,500 | $250K | 20 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PBLS)
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 41.4 (low 40, high 45).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | HC Wainwright & Co. | Initiated | Buy | $40 |
| 2026-07-06 | Guggenheim | Initiated | Buy | $40 |
| 2026-07-06 | Leerink Partners | Initiated | Outperform | $40 |
| 2026-07-06 | B of A Securities | Initiated | Buy | $45 |
Total return (dividends reinvested) (PBLS)
| 1Y (from 2026-06-10) | 5Y (from 2026-06-08) | |
|---|---|---|
| Total return | -14.8% | -1.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | — | — |
| Volatility (annualized) | 74.1% | 77.4% |
| Max drawdown | -45.5% (Sep 2026→Oct 2026) | -45.5% (Sep 2026→Oct 2026) |
PBLS company outlook (results filed Aug 13, 2026)
- “The Company's cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund its operations into 2030.”
Quoted word-for-word from the SEC 8-K results press release.
PBLS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.38 | $0.00 | — | $500,000 | 3 |
| Next quarter (ends Dec 2026) | $-0.40 | $0.00 | — | $1.0M | 3 |
| Current fiscal year (ends Dec 2026) | $-2.58 | $0.00 | — | $1.2M | 3 |
| Next fiscal year (ends Dec 2027) | $-2.19 | $0.00 | — | $4.8M | 3 |
PBLS options: expected move
Options price a move of about ±24.2% (±$8.98) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 1 reports the stock moved ±0.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 76.4% | ±24.2% |
| Feb 19, 2027 | 119 | 74.0% | ±36.4% |
| May 21, 2027 | 210 | 72.5% | ±44.6% |
30-day implied volatility 72.8% vs 90.2% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:31 UTC)
| Price | USD 26.92 |
|---|---|
| Change | ▼ 3.34% (down) |
| Previous Close | USD 27.85 |
| Open | USD 28.03 |
| Day Range | USD 26.58 – 28.29 |
| 52-Week Range | USD 22.66 – 42.49 |
| Volume | 911,946 shares |
| Market Cap | $3.33B |
| Exchange | NMS |
Technical Analysis (PBLS)
Nexqual's technical model rates PBLS "STRONG SELL" based on 0 bullish and 5 bearish signals across 94 daily candles, as of October 23, 2026 at 10:31 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.75 (neutral) |
| vs SMA50 | Below (USD 34.34) |
| MACD | -2.34 (negative) |
Analyst Ratings (PBLS)
Wall Street analysts rate PBLS "Buy" based on 6 analysts, with a mean price target of USD 41.4 (range USD 40–45), per Nexqual as of October 23, 2026 at 10:31 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 41.4 |
| High Target | USD 45 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (PBLS)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.38 |
| Revenue Estimate | $500,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.12 vs est -0.24 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:31 UTC.
Financials & Fundamentals (PBLS)
| Total Revenue | $148,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -34382.43% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.05 |
| Current Ratio | 17.91 |
| Total Cash | $1.12B |
| Total Debt | $47.51M |
Source: Nexqual, October 23, 2026 at 10:31 UTC.
Financial Health Score (PBLS)
Nexqual rates Parabilis Medicines, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:31 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.12B cash and investments vs $6M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$111M (TTM) |
| Efficiency | Mixed — No data |
Ownership (PBLS)
| Insider Ownership | +7.03% |
|---|---|
| Institutional Ownership | +82.47% |
| Shares Outstanding | 121.95M |
| Float | 82.07M |
| Short % of Float | +6.77% |
Source: Nexqual, October 23, 2026 at 10:31 UTC.
Leadership (PBLS)
Parabilis Medicines, Inc. is led by Mathai Mammen, CEO, President, Treasurer & Chairman, per Nexqual as of October 23, 2026 at 10:31 UTC.
| CEO, President, Treasurer & Chairman | Mathai Mammen |
|---|---|
| Scientific Co-Founder, Executive Vice President & Head of Platform | John McGee |
| Chief Financial Officer | Thomas Rodolpho Kotarakos |
| Executive Vice President of Discovery Biology | Jonathan Hurov |
| Executive Vice President of Discovery Science | Markus Haeberlein MSc |
Major Backers & Investors (PBLS)
Notable institutional backers of Parabilis Medicines, Inc. include RA Capital Management, L.P., FMR, LLC, Arch Venture Management, Llc, according to Nexqual as of October 23, 2026 at 10:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 23.73% |
| FMR, LLC | 8.44% |
| Arch Venture Management, Llc | 5.26% |
| venBio Partners LLC | 4.32% |
| Alphabet Inc. | 4.03% |
| Nextech Invest, Ltd. | 3.82% |
| Cormorant Asset Management, LP | 3.78% |
| Regeneron Pharmaceuticals Inc | 3.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.99% |
Source: Nexqual, October 23, 2026 at 10:31 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:31 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt